Last reviewed 2026-04-23 · How we verify

monoclonal antibody cA2

cA2 targets the CD19 protein on B cells to induce their destruction.

cA2 targets the CD19 protein on B cells to induce their destruction. Used for Relapsed or refractory B-cell non-Hodgkin lymphoma, Relapsed or refractory follicular lymphoma.

At a glance

Mechanism of action

cA2 is a monoclonal antibody that selectively binds to the CD19 protein on the surface of B cells, marking them for destruction by the immune system. This mechanism of action is specific to B cell malignancies and autoimmune diseases where B cells are overactive.

Approved indications

• Relapsed or refractory B-cell non-Hodgkin lymphoma
• Relapsed or refractory follicular lymphoma

Common side effects

• Neutropenia
• Thrombocytopenia
• Anemia

Key clinical trials

• Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt
• Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission (NA)
• A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (PHASE3)
• Combined Immunosuppression for Pediatric Crohn's Disease (PHASE4)
• A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
• Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer (PHASE1)
• Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial (PHASE4)
• Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.